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Objective To estimate the health and economic impact of feeding partially hydrolyzed formula–whey (PHF-W)
instead of standard cow’s milk formula (CMF) for the first 4 months of life among US infants at high risk for devel-
oping atopic dermatitis (AD).
Study design A Markov model was developed integrating published data, a survey of US pediatricians, costing
sources andmarket data, and expert opinion. Keymodeled outcomes included reduction in AD risk, time spent post
AD diagnosis, days without AD flare, and AD-related costs. Costs and clinical consequences were discounted at
3% annually.
Results An estimated absolute 14-percentage point reduction in AD risk was calculated with the use of PHF-W
compared with CMF (95% CI for difference, 3%-22%). Relative to CMF, PHF-W decreased the time spent post-
AD diagnosis by 8.3 months (95% CI, 2.78-13.31) per child and increased days without AD flare by 39 days
(95% CI, 13-63) per child. The AD-related, 6-year total cost estimate was $495 less (95% CI, $813 to $157)
per child with PHF-W ($724 per child; 95% CI, $385-$1269) compared with CMF ($1219 per child; 95% CI,
$741-$1824).
Conclusion Utilization of PHF-W in place of CMF as the initial infant formula administered to high-risk US in-
fants not exclusively breastfed during the first 4 months of life may reduce the incidence and economic burden
of AD. Broad implementation of this strategy could result in a minimum savings of $355 million per year to
society. (J Pediatr 2015;166:1145-51).
A
topic dermatitis (AD) is an increasingly prevalent chronic skin disease which typically presents during infancy.1 In the
US, AD affects 11%-17% of children.2,3 More than 50% of children with ADwill develop asthma and allergies in the first
few years of life.4 Pediatric AD is associated with a considerable resource use, economic, and quality of life burdens.1,5-7
Results from the German Infant Nutritional Intervention (GINI) study demonstrated that infants with atopic heredity fed a
standard intact protein cow’s milk formula (CMF) during the first 4 months of life had a higher incidence of AD up to age
10 years compared with those fed a partially hydrolyzed 100% whey-based formula (partially hydrolyzed formula–whey
[PHF-W]) or an extensively hydrolyzed casein formula (extensively hydrolyzed formula–casein [EHF-C]) during the firstFrom the 1Pharmerit International, Bethesda, MD;
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Nestle ResearchCenter, Lausanne, Switzerland, which is4months of life.8 These findings, from the largest independent study on this topic
to date, have been observed or confirmed in several subsequent studies, including
meta-analyses.9-12 As a result, the use of hydrolyzed formulas is considered a
viable AD risk-reduction strategy in high-risk formula-fed infants by US and Eu-
ropean organizations.13-15
In the US, PHF-W is marketed for routine use in healthy infants from birth,
and the cost is about the same as for intact CMFs. In contrast, EHF-C is typically
reserved for infants with special nutritional needs and not typically used in
healthy infants from birth. EHF-C costs more than routine intact CMFs and
may require a physician’s prescription under the Special Supplemental Nutrition
Program for Women, Infants, and Children.
The use of PHF-W in high-risk infants has been found to be cost-effective and/
or cost-saving compared with CMF in several developed countries, including
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AD Atopic dermatitis
ADCS Atopic dermatitis-controlled state
CMF Cow’s milk formula
EHF-C Extensively hydrolyzed formula–casein
GINI German Infant Nutritional Intervention
PHF-W Partially hydrolyzed formula–whey
PSA Probabilistic sensitivity analysis
uSA Univariate deterministic sensitivity analysis
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THE JOURNAL OF PEDIATRICS  www.jpeds.com Vol. 166, No. 5Germany,16 Australia,17 and France.18 Similar information is
lacking for the US, however. In the present study, we used es-
tablished health economic mathematical modeling tech-
niques19,20 to estimate the economic impact of feeding US
infants at high-risk for developing AD with PHF-W instead
of CMF for the first 4 months of life.Methods
Our analysis was conducted using Markov cohort modeling
techniques,21,22 adopting a US societal perspective to include
direct medical (eg, physician visits), direct nonmedical (eg,
transportation costs for physician visits), and indirect (eg, pro-
ductive time lost attending a sick child) costs associated with
formula feeding and AD treatment regardless of the party ul-
timately bearing these costs. Consistent with the GINI study,23
a 6-year time horizon was adopted to capture the longer-term
impact of this early, short-term nutritional intervention. Like-
wise, the target population (high-risk infants, defined as hav-
ing at least 1 biologic parent or sibling with an allergic disease
history), age at formula initiation, formula feeding duration,
and AD incidence were based on the GINI study.24Model Structure
Our model follows for up to age 6 years a simulated cohort of
newborns who initiated a 4-month feeding course of PHF-W
or CMF (Figure 1; available at www.jpeds.com). All formula
use was assumed to continue until age 12 months using age-
and nutrition requirement–appropriate volumes. Over time,
it was assumed that a percentage of children developed AD,
based on the GINI study, and as a result were treated by: (1)
a change in infant formula only; (2) the addition of
pharmacotherapy only with no change in formula; or (3) a
change in infant formula and addition of pharmacotherapy.
These approaches were selected in accordance with previous
models (eg, that of Iskedjian et al),18 a US survey of 101
pediatricians on the management patterns of AD in infants
and toddlers (children aged #36 months),25 and the opinion
of 4 clinicians with expertise in treating pediatric AD. Infants
who may have responded to a given formula change were
assumed to continue on it until age 12 months or their next
AD flare. Children who responded to pharmacotherapy were
assumed to finish their treatment course and remained on
their assigned formula until age 12 months. Thus, from year
1 through year 6, the pharmacotherapy-only treatment
approach was used exclusively.
In this model, treatment response rates were assumed to be
assessed every 2 weeks and determined the speed at which AD
symptoms resolved and children were transitioned to an AD-
controlled state (ADCS). Children in the ADCS were at risk
for acute dermatitis flares, which were treated with generally
treatment algorithms as the initial AD event. Mortality risk
unrelated to AD was included as well, to account for lost
PHF-W investment in cases of premature death (for
simplicity, not shown in Figure 1).261146Model Inputs
Several model inputs were obtained from a 2011 survey of
101 US pediatricians on the management patterns of AD in
infants and toddlers (children aged #36 months).25 The
design and key results of that survey are available elsewhere.25
In brief, a convenience sample of US practicing pediatricians,
the majority from the 25 most populous states, was identi-
fied. Survey questions assessed physician characteristics,
referral patterns, laboratory test use, emollient use, treatment
approach (based on age, severity, and symptom location, ie,
face or trunk and extremities), recurrence, and hospitaliza-
tion. Additional questions were aimed at quantifying AD
treatment-associated costs. Questions regarding dietary
management were defined as formula changes and were
limited to infants (age <12 months) not exclusively breastfed.
A pharmacologic approach was defined as prescribing or sug-
gesting active medications.
The age-stratified biweekly AD probabilities for CMF
(Table I; available at www.jpeds.com) were obtained using
the linear interpolation of the 1-, 3-, and 6-year cumulative
incidence data from the GINI study.23 The corresponding
probabilities for PHF-W were derived on the basis of the
cumulative relative risk from the same study, by multiplying
the adjusted relative risk by the 6-year cumulative
incidence.23 The case severity distribution (Table I) was
derived from the US pediatrician survey. The distribution of
treatment modalities and their corresponding response rates
by age and initial severity of AD presentation, as well as flare
risk by age and severity, were obtained from the US
pediatrician survey (Table I).
Daily formula volume intake was estimated using unpub-
lished data (unpublished data, Nestle Nutrition, July 3, 2013)
from the Feeding Infants and Toddlers Study.27,28 All infant
formula acquisition prices and relative market shares were
estimated using Nielsen data (unpublished data, Nestle
Nutrition, June 5, 2013). The cost of the initially assigned for-
mulas were estimated as $16.13/356 g for PHF-W and $16.13/
353 g for CMF. Up to 2 treatment formula changes were al-
lowed in the event that AD developed and treatment included
a switch from initially assigned formula to a treatment for-
mula. The latter included EHF-C, an amino acid-based for-
mula, a soy-based formula, and, for patients assigned CMF,
PHF-W, and vice-versa, in proportions reported in the US
pediatrician survey. Treatment formula costs were based on
the acquisition prices of each type of formula and their rela-
tive usage frequency, as reported in the US pediatrician sur-
vey. Only the additional costs incurred as a result of feeding
with an alternative infant formula above and beyond the cost
of CMF were considered, because infants would be fed with
formula until age 12 months when not exclusively breastfed.
Pharmacotherapy regimen utilization was determined us-
ing data from the US pediatrician survey, supplemented with
clinical expert opinion (Table II; available at www.jpeds.
com) and corresponding costs were obtained from drug
price references,29 including online retailers (eg, http://
www.google.com/shopping) for over-the-counter products.Bhanegaonkar et al
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assumed in 89.7% of cases of mild AD and 93.4% of cases
of moderate/severe AD.
Annual pediatrician visit numbers associated with AD
treatment (specifically, 2.45 visits for those with mild AD
and 5.78 visits for those with moderate/severe AD, excluding
the initial visits at AD presentation) were derived from the
US pediatrician survey. Clinical expert opinion was used to
support the assumptions that proportions of visits made to
pediatricians vs specialists ranged from 27% to 89%, depend-
ing on the severity of initial AD presentation, age, and type of
visits (ie, initial or follow-up). Costs of pediatrician visits
($52.32) and specialist visits ($86.47) were based on national
average reimbursement figures based on Current Procedural
Terminology codes,30,31 taking into account a mix of com-
mercial and public insurance.32
A child presenting with AD was assumed to be eligible for
various tests (eg, skin prick, specific IgE, radioallergosorbent
test, bacterial culture) in proportions varying from 0% to
20% depending on the specific test and the initial severity
of AD presentation, as reported in the US pediatrician survey.
The costs of the tests were obtained from the Ingenix Na-
tional Fee Analyzer 2013,31 reflecting a mix of public and pri-
vate payers.30,32 Based on the foregoing, the estimated
amount spent on tests was $8.50 for mild AD cases and
$31.37 for moderate/severe AD cases.
Indirect costs included the time lost to take care of a child
with AD, assumed to be 4 hours at the time of initial AD
development plus 2 hours for each subsequent physician
visit. The time lost was valued at $15.20/hour, based on the
average hourly wage ($23.98)33 adjusted for 63.4% labor
force participation.34 Finally, travel costs to and from a phy-
sician’s office was valued at $3.13 (representing an average
distance traveled for pediatric services of 5.15 miles35 at a
cost of $0.61 per mile traveled36).
In accordance with economic research guidelines,20 all
costs and effects occurring after the first year were discounted
at a rate of 3%.
Outcome Measures and Analyses
Base case outcomes for each treatment arm (ie, CMF and
PHF-W) included the proportion of children developing
AD, the average number of months a child was expected to
have AD (ie, from the time of AD diagnosis to the end of
the 6-year period), and the number of days without AD flare.
Differences between treatment arms were calculated and the
relative economic value of PHF-W vs CMFwas formally eval-
uated using incremental cost-effectiveness ratios—calculated
by dividing the difference in cost by difference in outcome
between the 2 formulas—including the incremental cost
per AD case avoided and cost per AD-free day gained.
Univariate deterministic sensitivity analyses (uSAs) and
multivariate probabilistic sensitivity analyses (PSAs) were con-
ducted to assess the impact of model parameter uncertainty on
the results. Specifically, a deterministic uSA was conducted on
individual model parameters, keeping the base case values for
other parameters in the model unchanged. In the multivariateEconomic Burden of Atopic Dermatitis in High-Risk Infants Rece
Whey-Based FormulaPSA, the model outcomes were replicated 5000 times using a
different value for each input parameter derived from specified
distributions. These 5000 PSA results were then used to esti-
mate nonparametric bootstrapped 95% CIs around all re-
ported mean outcome values.20 Distribution selected for key
epidemiologic and treatment patterns (eg, beta) are reported
in Table I. Uniform distributions were used for costs, with
variations of 25% around base case values.
Results
Modeled health outcomes were significantly better in the
children receiving PHF-W than in those receiving CMF
(Table III). This finding is consistent with the GINI study
results,23 on which the present model was based.
Specifically, feeding of PHF-W instead of CMF resulted in
an absolute 14 percentage-point reduction in AD incidence
(95% CI for difference, 3%-22%), a mean 8.3-month
reduction in the total time spent following an AD diagnosis
as a result of reduction in incidence or delayed in onset of
AD (95% CI for difference, 2.78-13.31 months), and a
mean 39-day increase in days without AD flare (95% CI for
difference, 13-63 days).
The overall total net cost was $495 (95% CI for difference,
$813 to$157) less for high-risk children initially fed PHF-
W ($724 per child; 95% CI, $385-$1269) compared with
CMF ($1219 per child; 95% CI, $741-$1824) over the 6-
year time horizon regardless of whether or not the child
developed AD. Total costs were driven primarily by pharma-
cologic treatment, followed by physician visits. Net cost sav-
ings with PHF-W were predicted to occur almost
immediately and to improve over time (from $54 by the
end of year 1 to $495 by the end of year 6; Figure 2),
because formula costs were virtually identical, whereas AD
incidence, and hence costs, diverged almost instantly.
Because the use of PHF-W was associated with reductions
in the number of AD cases and increases in AD-free days rela-
tive to CMF, as well as with cost savings, it was considered a
dominant strategy over CMF. This dominance was also
observed in 99.72% of 5000 multivariate PSA simulations
(Figure 3).
The factors of greatest influence on the difference in costs
between the PHF-W and CMF cohorts in uSA were AD prob-
ability in the CMF group (ie, background incidence) and AD
relative risk between the CMF and PHF-W groups. Specif-
ically, the cost difference between the 2 groups increased
with higher background AD incidence with CMF and higher
reductions in risk for PHF-W relative to CMF. Other vari-
ables with a minor impact on the results included infant for-
mula cost, discount rates, and risk of flare. Most other
variables when analyzed alone had no meaningfully impact
on the cost difference.
Finally, the average total direct and indirect (undis-
counted) estimated cost of developing AD within the first
6 years of life was $3284 per patient with AD. The average
annual total direct and indirect (undiscounted) estimated
cost for an incident AD case was $787 (including $659 iniving Cow’s Milk or Partially Hydrolyzed 100% 1147
Table III. Base case model results (discounted) for a healthy formula-fed infant with a positive family history of AD
Variables
Initial formula used
PHF-W CMF Difference
Formula risk reduction, $* 1.16 - 1.16
Formula treatment, $ 1.84 4.22 2.38
Physician visits, $ 219.22 368.27 149.05
Pharmacotherapy, $ 381.02 641.25 260.23
Diagnostic testing, $ 3.50 5.51 2.01
Hospitalization, $ 1.64 2.59 0.95
Indirect costs, $ 118.10 197.60 79.50
Total costs, $, mean (95% CI) 724.16 (385-1269) 1219.45 (741-1824) 495.29 (813 to 157)
Proportion of children developing AD, %, mean (95% CI) 24 (0.13-43) 38 (23-54) 14 (22 to 3)
Days with AD flare, mean (95% CI) 56 (31-97) 95 (58-138) 39 (63 to 13)
Months of life post-AD diagnosis, mean (95% CI) 12.1 (6.6-19.9) 20.3 (12.1-28.9) 8.3 (13.3 to 2.9)
ICER cost per AD case avoided, $ Dominant (ie, 3590)†
ICER cost per days without AD flare gained, $ Dominant (ie, 12.86)†
ICER, incremental cost-effectiveness ratio.
Dominance refers to a situation in which effectiveness is higher and costs are lower.
*The formula risk reduction and formula management costs are only the excess costs over and beyond the cost of feeding using CMF.
†Negative ICER values suggest a net cost savings due to an avoided AD case and gain in AD-free day indicating dominance of PHF-W over CMF.
THE JOURNAL OF PEDIATRICS  www.jpeds.com Vol. 166, No. 5direct costs), regardless of the type of formula fed during in-
fancy. The estimated total annual number of physician visits
per AD case was approximately 3.58 visits.
Discussion
Our mathematical model suggests that the use of PHF-W
instead of CMF for the first 4 months of life should result
in a reduced clinical burden of AD and net cost savings. These
findings are consistent with results from other developed
countries.16-18 A strength of this analysis is the reliance on
a US-based survey of pediatricians25 as a source of AD treat-Figure 2. Effect of initial formula administration on cumulative AD
atopic disease, by year. Cumulative overall costs were lower for h
CMF across all years regardless of whether or not the child deve
1148ment pattern and outcome inputs. In contrast, most previous
studies relied solely or heavily on expert opinion for resource
utilization-related model inputs.16,18
The cost-effectiveness of decreasing the risk of AD in US
children depends in large part on 3 factors: formula costs,
AD incidence, and AD treatment costs. First, the prices of
the PHF-W and CMF used in this study were almost identical
owing to market dynamics; thus, infant formula cost did not
influence the results. Second, the absolute 14-percentage point
difference in AD incidence between PHF-W and CMF fed in-
fants in the present analysis reflects the GINI study results23
and is consistent with that reported in previous studies.9-12,37-related total costs in healthy infants with a family history of
igh-risk children initially fed PHF-W compared with those fed
loped AD.
Bhanegaonkar et al
Figure 3. Scatterplot of difference in costs and days without AD flare. Each black dot represents 1 of the 5000 multivariate PSA
simulations.
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reduction is the average annual cost of AD treatment for a pa-
tient aged 0-6 years. The estimated annual direct cost of AD
treatment was $659, and the total cost was $787. If not conser-
vative, these estimates are consistent with previously reported
pediatric AD treatment costs, which have varied from $7057
(including private insurer costs only) to $11607 (including
Medicaid costs only) and $13145 (including costs to private in-
surers and families) (all values inflation-adjusted to 2013 dol-
lars). In addition, 3.58 AD physician visits were estimated to
occur annually per patient with AD consistent, if not conser-
vative, compared with values from other published
studies,38,39 in particular the 5.4 annual visits assumed in a
German economic analysis of the GINI study.16
Thus, all 3 of the aforementioned factors affecting cost-
effectiveness were based on and/or consistent with the litera-
ture and contributed to the estimated cost savings associated
with the use of PHF-W instead of CMF in formula-fed high-
risk infants.
These results can help estimate the broader, national impact
of feeding PHF-W instead of CMF to US infants who are not
exclusively breastfed, regardless of family history of atopic dis-
ease. If one assumes that of the estimated 4 million children
born in the US annually,40 approximately 52% are not exclu-
sively breastfed,41 then 31% of nonexclusively breastfed infants
are born with a family history of AD, and if all are assumed to
receive CMF, then the (undiscounted) savings for the high-risk
population alone is approximately $355 million per year (ie,
$787/year  0.70 year  4 million  52%  31%).
To further extrapolate the savings that may be achieved
among US children without a family history of atopic diseaseEconomic Burden of Atopic Dermatitis in High-Risk Infants Rece
Whey-Based Formularequires some assumptions regarding both the incidence of
AD and the impact of PHF-W compared with CMF in that
population. For instance, if one assumes that the risk of
AD among children without a family history is one-half of
that in those with a family history, and that the relative reduc-
tion in the incidence of AD for PHF-W relative to CMF is the
same in both populations, then the (undiscounted) savings of
feeding PHF-W compared with CMF in those without a fam-
ily history is approximately $395 million (ie, $787/
year  0.70 year  50%  4 million  52%  100% 
31%). Under such a scenario, the maximum potentially
achievable (undiscounted) savings for the entire population
(with or without a family history) is approximately $750
million per year. Similarly, if all nonexclusively breastfed in-
fants in the US received PHF-W instead of CMF, then the to-
tal estimated number of AD physician visits avoided could be
extrapolated to 3.4 million visits, including 1.6 million visits
for infants and children with a family history.
Our study results should be interpreted in light of the
following limitations. First, the US pediatrician survey on
which the analysis is largely based did not always differentiate
between the 2 age groups (0-12months and >1 year), and thus
the overall percentage distribution of patients with AD based
on disease severity, initial diagnostic testing, and disease flare
probability did not differ by age. Second, the model assumed
that all infants would stop receiving infant formula as a nutri-
tion source after 12 months, and thus only pharmacologic
treatments were used for children aged 1-6 years. In reality, it
is possible that children aged $1 year may still be fed with
toddler formula. Third, although reliance on a survey of 101
physicians allowed for a more detailed assessment of AD costs,iving Cow’s Milk or Partially Hydrolyzed 100% 1149
THE JOURNAL OF PEDIATRICS  www.jpeds.com Vol. 166, No. 5the detailed questions regarding infant formula might have
caused respondents to overreport nutritional interventions at
the expense of themore costly pharmacologic approach, which
in turn would slightly overestimate the cost savings associated
withAD risk reduction. Finally, somepossible lost productivity
cost due to AD (including, eg, time lost for daily care of a child
with AD) was not considered in our analysis. As a result, indi-
rect costs accounted for only 16% of AD-related costs, despite
ample evidence indicating that such costs likely account
for a significantly greater proportion of total AD-related
costs.18,42,43 As such, the estimated savings associated with
PHF-Wuse aremost likely underestimated.Other general lim-
itations inherent to anymodeling study, such as the simplifica-
tion of a complex reality and the use of assumptions from
multiple sources, apply to the present analysis as well.
Based on the mathematical model used herein and its as-
sumptions, the use of PHF-W instead of CMF in healthy in-
fants with a family history of allergy who are not exclusively
breastfed may be expected to help reduce the incidence of AD
and to increase the number of days without AD flares. In the
US, the use of PHF-Wmay provide a net cost savings of $495
per child to the healthcare system and society. Full imple-
mentation of this approach could result in an estimated min-
imum savings of $355 million per year to society and the
avoidance of 1.6 million visits per year. Given these estimates
and the continuing pressure on the healthcare system
imposed by chronic conditions,19 implementing this strategy
should be a consideration for physicians, particularly pedia-
tricians, as well as US private and public health care payers. n
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Figure 1. Schematic diagram of the Markov decision model for healthy children at high risk for AD. Children not exclusively
breastfed with a family history of allergy enter into the model at birth [A] and initiate a 4-month course of PHF-W or CMF [B].
Children who develop AD [C] are treated by 1 of 3 approaches: formula change only [D], formula change combined with first-line
pharmacotherapy [E], or first-line pharmacotherapy only [F]. After first-line treatment, children either enter into the ADCS or, if no
response is seen, have a change in treatment regimen [G-N].
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Table I. Epidemiologic, clinical, and effectiveness inputs
Variables Base case
Value in uSA* Probability
distribution
for PSA SourceLow High
AD probability with CMF, % von Berg et al, 200823
0-1 y 16.80 6.96 29.85 Beta
>1-3 y 20.07 9.00 34.19 Beta
>3-6 y 8.42 0.18 29.66 Beta
AD cumulative relative risk; PHF-W vs CMF von Berg et al, 200823
0-1 y 0.54 0.33 0.89 Exponential
1-3 y 0.57 0.36 0.90 Exponential
3-6 y 0.82 0.40 1.70 Exponential
Proportion of mild cases, %, 0-6 y 73.20 72.63 73.82 Beta US pediatrician survey
Flare-up probability, %, 0-6 y US pediatrician survey
Mild AD 46.72 43.34 50.12 Beta
Moderate/severe AD 56.86 51.79 61.86 Beta
AD management 0-12 mo, mild AD, %† US pediatrician survey
Dietary 12.40 11.90 12.85 Dirichlet
Combined 48.20 48.59 47.85 Dirichlet
Medical 39.40 39.51 39.30 Dirichlet
AD management 0-12 mo, moderate/severe AD, %† US pediatrician survey
Dietary 12.40 11.61 13.17 Dirichlet
Combined 48.20 48.83 47.61 Dirichlet
Medical 39.40 39.56 39.22 Dirichlet
AD management 1-6 y, mild to severe AD, % US pediatrician survey
Medical 100 100 100 NA
Infant formula change response rate, % US pediatrician survey
For AD infants initially on PHF-W 32.90 26.56 39.56 Beta
For AD infants initially on CMF 32.50 26.15 39.19 Beta
Combination therapy response rate, mild AD, % US pediatrician survey
First-line 68.50 64.70 72.18 Beta
Second-line 69.30 62.54 75.67 Beta
Third-line 66.40 53.47 78.19 Beta
Combination therapy response rate, moderate/severe AD, % US pediatrician survey
First-line 59.00 51.87 65.95 Beta
Second-line 62.20 51.37 72.45 Beta
Third-line 65.20 47.91 80.63 Beta
First-line pharmacotherapy response rate, 0-12 mo, % US pediatrician survey
Mild AD 53.70 48.67 58.69 Beta
Moderate/severe AD 54.10 45.81 62.28 Beta
First-line pharmacotherapy response rate, 1-6 y, % US pediatrician survey
Mild AD 61.30 58.40 64.16 Beta
Moderate/severe AD 54.20 49.01 59.35 Beta
Second-line pharmacotherapy response rate, all ages, % US pediatrician survey
Mild AD 66.30 61.92 70.55 Beta
Moderate/severe AD 57.00 49.52 64.32 Beta
Third-line pharmacotherapy response rate, all ages, % US pediatrician survey
Mild AD 64.20 55.77 72.21 Beta
Moderate/severe AD 33.80 19.06 50.37 Beta
NA, not applicable.
*Owing to a lack of data sources, some value inputs were based on arbitrary variation rather than on the distribution assumption in the PSA to test the univariate sensitivity.
†All 3 categories were varied simultaneously instead of varying a single proportion of case distribution using a Dirichlet distribution, so that the proportions added up to 100%. This is a scenario
analysis rather than a uSA.
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Table II. Medical treatments used and acquisition costs by AD disease severity and age group
Age group
Percentage of patients with AD receiving treatment*
Acquisition cost
per unit, $
0-12 mo >1-6 y
AD severity at presentation Mild Moderate/severe Mild Moderate/severe
Treatment line 1 2 3 1 2 3 1 2 3 1 2 3 0-12 mo >1-6 y
Topical emollients (during and after flares) 90 90 90 93 93 93 90 90 90 93 93 93 11.27†,z 11.27†,z
Barrier repair topical therapy 4 7 2 16 7 2 5 40 1 13 14 2 148.00† 148.00†
Low-potency topical corticosteroids 40 42 1 26 10 0 37 43 22 28 12 1 65.40† 65.40†
Medium-potency topical corticosteroids 5 42 22 57 18 2 8 5 5 59 25 3 36.55† 54.81†
High-potency topical corticosteroids 0 2 4 5 16 1 0 4 7 6 5 10 6.66† 6.66†
Other topical anti-inflammatory agents 0 3 10 2 10 10 0 3 1 1 2 0 347.42† 347.42†
Antibacterial soap or cleanser 3 5 5 9 2 5 2 4 3 6 2 5 4.32†,z 4.32†,z
Topical antibiotics 2 1 1 1 8 1 2 4 2 1 6 1 15.05† 15.05†
Oral antihistamines 7 16 5 30 27 1 7 15 3 34 25 0 9.07† 9.06†
Other corticosteroid/immunosuppressant 0 1 0 1 10 1 0 0 0 1 0 0 67.44† 67.44†
Oral antibiotics 0 2 1 6 5 4 0 2 0 3 3 0 24.81† 31.20†
*Source: US pediatrician survey for percentage of patients with AD using each treatment and clinical expert opinion for specific brands (not shown).
†RED BOOK Online.29
zCosts for over-the-counter products were obtained from online retailers (eg, http://www.google.com/shopping).
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